Can Psychedelics Cure Chronic Pain? This Promising Study Lays Groundwork for Future Clinical Trials

Nine out of the 11 chronic pain sufferers interviewed say they experienced some kind of lasting pain reduction while self-medicating with psychedelics.
PharmaTher Believes Ketamine Could Treat This Rare Neurological

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.

New Evidence Microdosing Psychedelics Reduces Anxiety and Depression

This study also showed microdosers were less likely to use alcohol and were most likely to abstain from consuming alcohol entirely.

How Dr. Monnica Williams Created Canada’s First Psychedelic Master’s Degree Program: ‘Nobody Took Me Seriously’

After two long years of preparing documents and presenting to various committees, the program is in its final stages, and the University of Ottawa will soon begin accepting applications for the fall semester.

Jada Pinkett Smith Tackles Exclusion of People of Color From Psychedelic Research on ‘Red Table Talk’

“We know nothing scientific about psychedelics and people of color and how appropriate our treatments are for people in those communities," says psychedelic researcher Dr. Monnica Wiliams.

American Overdose Deaths Reach Record High During COVID Pandemic—And New Study Shows Psychedelics Can Help

“After adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” researchers say.
How does Time of Day Influence LSD Microdosing? New Study Hopes to Find Out

How does Time of Day Influence LSD Microdosing? New MindMed Study Hopes to Find Out

"Our goal is to provide insight on key parameters that may impact and explain the mechanisms behind low-dose treatments," says MindMed Executive President Dr. Miri Halperin Wernli.

Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce

“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.
Why We're Excited About Compass Pathways New Clinical Trial Treating PTSD With

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2…